The GUSTO trial and the open artery theoryCALIFF, R. M.European heart journal. 1997, Vol 18, Num DEC, pp F2-F10, issn 0195-668X, SUPFConference Paper

Cardiac markers in acute coronary syndromes-refining our knowledgeCALIFF, R. M.European heart journal. 2003, Vol 24, Num 2, pp 136-137, issn 0195-668X, 2 p.Article

Update on thrombolytic agents: emerging options for AMI managementCALIFF, R. M; MASERI, A.European heart journal. 1997, Vol 18, Num DEC, issn 0195-668X, 37 p., SUPFConference Proceedings

Chronic ischemic heart diseaseGENT, M; CALIFF, R. M.The American heart journal. 2000, Vol 139, Num 4, pp S182-S188, issn 0002-8703Conference Paper

Glycoprotein IIb/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation : A review of trial reportsKONG, D. F; CALIFF, R. M.Drugs (Basel). 1999, Vol 58, Num 4, pp 609-620, issn 0012-6667Article

The concept of equivalence and its application to the assessment of thrombolytic effectsHAMPTON, J. R.European heart journal. 1997, Vol 18, Num DEC, pp F22-F27, issn 0195-668X, SUPFConference Paper

Acute ischemic syndromesCALIFF, R. M.The Medical clinics of North America. 1995, Vol 79, Num 5, pp 999-1024, issn 0025-7125Article

Scorecard cardiovascular medicine : its impact and future directionsTOPOL, E. J; CALIFF, R. M.Annals of internal medicine. 1994, Vol 120, Num 1, pp 65-70, issn 0003-4819Article

Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activatorSMALLING, R. W.European heart journal. 1997, Vol 18, Num DEC, pp F11-F16, issn 0195-668X, SUPFConference Paper

Combination therapy for acute myocardial infarction : Fibrinolytic therapy and glycoprotein IIb/IIIa inhibitionCALIFF, R. M.The American heart journal. 2000, Vol 139, Num 2, pp S33-S37, issn 0002-8703, 2Article

Glycoprotein IIb/IIIa blockade and thrombolytics : Early lessons from the speed and GUSTO IV trialsCALIFF, R. M.The American heart journal. 1999, Vol 138, Num 1, pp S12-S15, issn 0002-8703, 2Article

Use of GP IIb/IIIa inhibitors in coronary syndromes: state of the art. International roundtableCALIFF, R. M; SIMOONS, M. L.European heart journal. 1998, Vol 19, Num AVR, issn 0195-668X, 68 p., SUPDConference Proceedings

Restenosis : the cost to societyCALIFF, R. M.The American heart journal. 1995, Vol 130, Num 3, pp 680-684, issn 0002-8703, 2Conference Paper

Cardiogenic shockCALIFF, R. M; BENGTSON, J. R.The New England journal of medicine. 1994, Vol 330, Num 24, pp 1724-1730, issn 0028-4793Article

At home thrombolysisCALIFF, R. M; HARRELSON-WOODLIEF, S. L.Journal of the American College of Cardiology. 1990, Vol 15, Num 5, pp 937-939, issn 0735-1097, 3 p.Article

Tissue plasminogen activator: why the backlash?TOPOL, E. J; CALIFF, R. M.Journal of the American College of Cardiology. 1989, Vol 13, Num 7, pp 1477-1480, issn 0735-1097, 4 p.Article

Should the emergence of new agents change the management of patients with acute coronary syndromes without ST-segment elevation?CALIFF, R. M; HOLMES, D. R.The American heart journal. 1999, Vol 138, Num 6, pp S586-S594, issn 0002-8703, 2Conference Paper

Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart diseaseCALIFF, R. M; MARK, D. B.The American heart journal. 1997, Vol 134, Num 5, pp S88-S96, issn 0002-8703, SUPConference Paper

Myocardial reperfusion 1988: practical considerationsTOPOL, E. J; CALIFF, R. M.Journal of the American College of Cardiology. 1988, Vol 12, Num 6, issn 0735-1097, 92 p., suppl. ASerial Issue

Risk stratification after myocardial infarctionPETERSON, E. D; SHAW, L. J; CALIFF, R. M et al.Annals of internal medicine. 1997, Vol 126, Num 7, pp 561-582, issn 0003-4819Article

Targeting new thrombolytic regimens at specific patient groups : implications for research and cost-containmentMASERI, A; ANDREOTTI, F.European heart journal. 1997, Vol 18, Num DEC, pp F28-F35, issn 0195-668X, SUPFConference Paper

How much do we gain by reducing time to reperfusion therapy ?CALIFF, R. M; NEWBY, L. K.The American journal of cardiology. 1996, Vol 78, Num 12A, pp 8-15, issn 0002-9149Conference Paper

Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trialsCALIFF, R. M; HARRELSON-WOODLIEF, L; TOPOL, E. J et al.Circulation (New York, N.Y.). 1990, Vol 82, Num 5, pp 1847-1853, issn 0009-7322Article

Cardiac protection : Evolving role of angiotensin receptor blockersCALIFF, R. M; COHN, J. N.The American heart journal. 2000, Vol 139, Num 1, pp S15-S22, issn 0002-8703, 2Article

Thrombolytic therapy for acute myocardial infarction : a reviewGRANGER, C. B; CALIFF, R. M; TOPOL, E. J et al.Drugs (Basel). 1992, Vol 44, Num 3, pp 293-325, issn 0012-6667Article